Study: vaporizing cannabis produces stronger effects
A double-blind study conducted from June 2016 to January 2017 at the Johns Hopkins University of Medicine Behavioral Pharmacology Research Center in Baltimore administered participants doses of 0mg (placebo), 10mg and 25mg of vaporized (via a Volcano from Storz and Bickel) and smoked cannabis to investigate differences in effects between the two modes of administration and as a function of dosage. It concluded that there was a significant difference in effects between vaporized and smoked cannabis.
The study assessed the effects of cannabis in subjective terms and by conducting cognitive and psychomotor performance tests. It also monitored cardiovascular vital signs and the concentration of THC in blood. The observed sample consisted of 17 healthy adults, 9 men and 8 women, who were not regular cannabis users and had not used cannabis in the 30 days prior to testing.
Study results
The results of taking cannabis differed significantly depending on whether it was smoked or vaporized. This may be due in part to the fact that combustion destroys part of the cannabinoids. At 10mg and on a scale of 1 to 100 the effects of cannabis were estimated at 46 by smoking and 69 by vaporization. However, cognitive effects remain moderate in both cases. With the 25 mg dose, the difference is reduced to 66 by smoking and 78 by vaporizing, but the reduction in cognitive and psychomotor abilities is more visible, with performance being lower compared to people given a placebo.
Taking vaporized cannabis resulted in increased subjective impairments and higher THC concentrations in the blood than with smoked cannabis (14.4 ng/ml, 10.2ng/ml). In addition, the study observed that THC concentration in the blood and cardiac activity peaked 30 minutes after dosing, and returned to normal around 3 to 4 hours after dosing. In contrast, subjective, cognitive and psychomotor changes persist for up to 6 hours after intake.
The study notes that the maximum dose in the study, 25 mg THC (0.187g weed at 13.4% THC), is significantly lower than the dose and concentration of conventional THC found in pre-rolled joints in U.S. stores. In dispensaries, it's common to find joints containing 1 gram of cannabis with a THC concentration of over 18%. Increasingly easy access to cannabis in the medical and recreational markets raises a number of questions that research has so far failed to address. The discovery of this difference between vaporized and smoked cannabis in adults who do not use cannabis regularly may inform the choice of healthcare professionals in referring their patients, or certain cannabis policies and regulations. These results may also be used to improve procedures for detecting severe cannabis intoxication.
-
Cannabis in France4 weeks ago
France Sets July as the Deadline for the Widespread Adoption of Medical Cannabis
-
Cannabis in Europe2 weeks ago
Bosnia and Herzegovina Continues to Roll Out Medical Cannabis Following Its Legalization
-
Cannabis in France2 weeks ago
France Submits the Long-Awaited Decree on the Reimbursement of Medical Cannabis to the Council of State
-
Cannabis in the U.S.2 weeks ago
The DEA Begins Hearings on the Federal Rescheduling of Cannabis
-
Cannabis in Ireland3 weeks ago
The Irish Parliament recommends decriminalizing all drugs
-
Business4 weeks ago
Sanity Group is expanding its presence in Switzerland through a distribution agreement with Astrasana
-
Cannabis in France4 weeks ago
Medical Cannabis in France: What the First Major Study Reveals About Its Actual Impact
-
Cannabis in Switzerland3 weeks ago
St. Gallen, Switzerland, Launches Its 8th Legal Cannabis Pilot Project


You must be logged in to post a comment Login